At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ultrasound Microbubble Destruction and Perfusion Quantification for Improving Radioembolization Therapy of Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, and 1 other intervention for Hepatocellular Carcinoma. Completed, enrolled 104 participants across 1 site.
Detailed Summary
This phase II trial studies how well perflutren protein-type A microspheres and contrast-enhanced ultrasound work in improving response to radioembolization therapy in patients with liver cancer. Ultrasound contrast agents, such as perflutren protein-type A microspheres, use gas microbubbles to improve image quality. Using contrast-enhanced ultrasound imaging will "pop" these microbubbles and cause tumors to become more sensitive to radiation therapies.
Study Details
Timeline
Interventions
Undergo standard of care Y-90 radioembolization
Given IV.
Undergo CEUS